Tofacitinib, an oral JAK1 and-3 inhibitor that is already approved for use in rheumatoid arthritis (RA), [107,108,109], is currently under evaluation for the treatment of both plaque psoriasis [110] and psoriatic arthritis [111,112,113]. The gene discussed is JAK1; the disease is rheumatoid arthritis.